Tag Archives: MDVN

Medivation Inc. (MDVN)

Medivation, Inc., a biopharmaceutical company, focuses on the development of small molecule drugs for the treatment of castration-resistant prostate cancer, Alzheimer?s disease, and Huntington disease. The company?s product candidates under clinical development include MDV3100, which is in Phase 3 development for the treatment of castration-resistant prostate cancer; and dimebon, which is in Phase 3 clinical trial for the treatment of Alzheimer?s disease and Huntington disease. It has collaboration agreements with Pfizer Inc. to develop and commercialize dimebon; and Astellas Pharma Inc. to develop and commercialize MDV3100. The company was founded in 2003 and is based in San Francisco, California.

News about MDVN

Verastem: Updates To Thesis
Shares of Verastem (VSTM) have fallen by over 35% since my article from September in which we took a look at top-line results from their pivotal DUO trial. Figure 1: VSTM daily advanced chart (Source: Finviz Elite) (Disclosure: Contains affiliate ...Read More>>>

Eni - Cars Aren't The Only Thing Italians Excel At
Eni (E) is an Italian multinational oil and gas company headquartered in Rome. With a $60 billion market cap, Eni is considered one of the global oil and gas super majors. Despite being a super major, Eni has had a difficult time since the start of t...Read More>>>

Todd Hagopian's Top Biotech Takeover Targets For 2017
Many biotech stocks took a beating as price gouging from the likes of Valeant (Nitropress), Mylan (epi-pens), and Turing (Daraprim) became a political issue during last year’s presidential campaign. Consequently, we enter 2017 with many compani...Read More>>>

Top 10 S&P 500 Dividend Stocks to Buy Now
Chasing yield when looking for dividend stocks to buy is one the most dangerous things an investor can do. But it’s also more tempting than ever. This prolonged period of ultra-low interest rates is almost forcing investors to take more risk tha...Read More>>>

3 Reasons Pfizer Is A Screaming Buy Right Now
Click to enlarge Pfizer (NYSE:PFE) hasn't had a good year, having both underperformed rivals such as Johnson & Johnson (NYSE:JNJ), and Merck (NYSE:MRK), as well as the S&P 500. PFE Total Return Price data by YCharts...Read More>>>